Renaissance Technologies LLC Has $3.55 Million Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Renaissance Technologies LLC grew its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 83.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 131,300 shares of the company’s stock after purchasing an additional 59,700 shares during the period. Renaissance Technologies LLC owned about 0.29% of Omnicell worth $3,554,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Omnicell by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after acquiring an additional 80,312 shares during the last quarter. Mutual of America Capital Management LLC raised its stake in shares of Omnicell by 197.9% during the 1st quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock worth $3,642,000 after purchasing an additional 82,774 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Omnicell by 61.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after buying an additional 228,093 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Omnicell during the 1st quarter valued at about $684,000. Finally, Cadian Capital Management LP bought a new stake in shares of Omnicell in the 4th quarter valued at approximately $2,446,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Price Performance

Shares of Omnicell stock opened at $43.02 on Monday. The firm has a fifty day moving average price of $40.75 and a two-hundred day moving average price of $32.80. The company has a market cap of $1.98 billion, a PE ratio of -93.52, a price-to-earnings-growth ratio of 47.34 and a beta of 0.83. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $46.47.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The company’s quarterly revenue was down 7.4% on a year-over-year basis. During the same quarter last year, the company earned $0.29 EPS. Analysts expect that Omnicell, Inc. will post 0.64 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on OMCL. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Wells Fargo & Company upped their price objective on shares of Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Benchmark restated a “buy” rating and set a $38.00 target price on shares of Omnicell in a report on Monday, July 15th. Barclays upgraded Omnicell from an “underweight” rating to an “equal weight” rating and upped their price target for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. raised their price objective on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $37.83.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.